Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of SZEY-2108 in Healthy Chinese Subjects
NCT06055777Phase 1Terminated
- Sponsor
- Suzhou Erye Pharmaceutical Co., Ltd.
- Start
- Sep 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SZEY-2108 in bacterial infection and Enterobacteriaceae infection, sponsored by Suzhou Erye Pharmaceutical Co., Ltd. Primary endpoint: Safety of single and multiple ascending doses of SZEY-2108. Started Sep 2023; status: terminated.
02
Drugs
SZEY-2108
03
Conditions
bacterial infectionEnterobacteriaceae infection
Beyond the preview
Go deeper on NCT06055777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06055777.